Dan Coatsworth

AstraZeneca shares plunged on July 9, 2026, after its nerve disease drug Wainua unexpectedly missed its primary endpoint in a late-stage trial for transthyretin amyloid cardiomyopathy. The trial failure clouds a projected $2 billion sales opportunity and intensifies pressure on the drugmaker’s long-term revenue strategy. AstraZeneca experienced a share price drop following the disclosure that … Read more